APPLICATION OF A NEW TYROSINKINASE INHIBITOR, ANLOTINIBA, IN OSTEOSARCOMA AND CHONDROSARCOMA Russian patent published in 2022 - IPC A61K31/4709 A61P35/00 

FIELD: medicine and pharmaceutics.

SUBSTANCE: inventions group relates to the field of medicine and pharmaceutics. The use of anlotinib and its pharmaceutically acceptable salt in the preparation of a drug for the inhibition of advanced and/or metastatic osteosarcoma is proposed. The group of inventions also relates to the use of anlotinib and its pharmaceutically acceptable salt as a cisplatin enhancer in the inhibition of advanced and/or metastatic osteosarcoma, and to the use of a pharmaceutical composition containing anlotinib or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier for inhibiting advanced and/or metastatic osteosarcoma.

EFFECT: anlotinib provides a significant inhibitory effect on the proliferation of osteosarcoma cell lines, induces cell cycle arrest in osteosarcoma cells, and can also inhibit the migration and invasion of osteosarcoma cells; anlotinib also enhances the cytolytic effect of cisplatin on osteosarcoma cells.

14 cl, 7 dwg, 1 tbl, 8 ex